J. Goldman & CO LP Roivant Sciences Ltd. Call Options Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ROIV
# of Institutions
311Shares Held
508MCall Options Held
1.26MPut Options Held
2.52M-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$838 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$836 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$688 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA41.7MShares$530 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$450 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.95B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...